Timothy A. Yap, MBBS, PhD, MRCP, BS. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. Presented at ASCO Annual Meeting, June 2, 2018.
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
(857) 259-3843 email@example.com